by Mallory Laur
We are happy to head into this RSV season with a new tool to protect infants after the CDC approved a monoclonal antibody. Nirsevimab (trade name BeyfortusTM), a form of passive immunization, is recommended as a single dose for babies younger than 8 months born during or entering their first RSV season and certain high-risk children ages 8-19 months entering their second RSV season. It is expected to be available this fall and will be covered by insurance as well as through Vaccines for Children. While equitable access is a concern, we are hopeful for the potential reduction in hospitalization for this vulnerable population. We will share more from KDHE as it becomes available.
Looking forward to this fall, KAAP will be hosting a webinar with FrameWorksA, a nonprofit research organization that partnered with the American Academy of Pediatrics on vaccine hesitancy research. FrameWorks will present a state-focused training on the latest vaccine messaging recommendations and guidance for how to advocate for expanding access to childhood and adolescent vaccination. The date and more information will be coming soon.
Please reach out at email@example.com with any questions or ways I can support you on vaccine-related efforts.